Aditya Bardia, MD, MPH
Massachusetts General Hospital Cancer Center, Harvard Medical SchoolAuthored Items
November 9, 2018 | November 2018 Vol 9, NO 11
Endocrine therapy (ET) is an established treatment for premenopausal women with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC). MONALEESA-7 (NCT02278120) was the first phase 3 randomized trial of a cyclin-dependent kinases 4 and 6 inhibitor (ribociclib) + ET in premenopausal women with HR+/HER2− ABC without prior ET for ABC.
Last modified: December 19, 2018